drugset / Trial / NCT06564194
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Phase 1
Active not recruiting
75 enrolled
Immorna Biotherapeutics, Inc.
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
Timeline
- Start
- 2024-09-25
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JCXH-108 | Unknown | — | Intramuscular |